nature biotechnology VOLUME 29 NUMBER 12 DECEMBER 2011 1 1 1 7 b r i e f c o m m u n i c at i o n s Somatic cells within an organism share the same genomic sequence, but when development occurs from the single-cell zygote, subsequent generations of cells acquire differential patterns of gene expression owing to alterations in chromatin structure and chemical modifications of the DNA, such as cytosine methylation. Reprogramming of somatic cells to pluripotency reverses this process of cell specification through epigenetic modification, and entails erasure of tissue-specific DNA methylation and re-establishment of the embryonic methylome. We have detected residual and aberrant tissue-specific DNA methylation in mouse iPSCs, which functions to confer epigenetic memory, biasing the differentiation potential of iPSCs toward lineages related to the donor cell 1,2 . Here we investigate whether epigenetic memory persists in human iPSCs. We reprogrammed neonatal CD34 + cells from umbilical cord blood cells and foreskin keratinocytes, representative cell types of distinct embryonic germ layers, mesoderm and ectoderm, whose
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We reprogrammed neonatal CD34 + cells from umbilical cord blood cells and foreskin keratinocytes, representative cell types of distinct embryonic germ layers, mesoderm and ectoderm, whose We compared bona fide human induced pluripotent stem cells (iPSCs) derived from umbilical cord blood (CB) cells and neonatal keratinocytes (K). As a consequence of both incomplete erasure of tissue-specific methylation and aberrant de novo methylation, CB-iPSCs and K-iPSCs were distinct in genome-wide DNA methylation profiles and differentiation potential. Extended passage of some iPSC clones in culture did not improve their epigenetic resemblance to embryonic stem cells, implying that some human iPSCs retain a residual 'epigenetic memory' of their tissue of origin. differentiation potential can be readily assayed in vitro (Fig. 1a and  Supplementary Fig. 1 ). The resultant iPSCs from at least two independent cord blood and three keratinocyte donors passed stringent pluripotency tests characteristically applied to human embryonic stem cells (ESCs) (Supplementary Methods). We then tested the potential of the CB-iPSCs and K-iPSCs to differentiate into keratinocytes 3 . In day-6 embryoid bodies, K-iPSCs displayed 9.4-fold higher expression of the gene encoding keratin 14, a marker of early keratinocyte differentiation ( Fig. 1b and Supplementary Fig. 2a) , and quantitatively, K-iPSCs yielded 23-fold more keratinocytes than CB-iPSCs ( Fig. 1c and Supplementary Fig. 2b ), indicating that K-iPSCs show enhanced keratinocyte potential relative to CB-iPSCs. Next, we differentiated multiple independent clones of CB-iPSCs and K-iPSCs in methylcellulose to test hematopoietic potential. Despite their reduced capacity for keratinocyte differentiation, differentiating cultures of CB-iPSCs produced an expected range of myeloid colony types, whereas K-iPSCs surveyed from multiple donors yielded relatively few hematopoietic colonies (Fig. 1d) . Multiple clones of CB-iPSCs consistently yielded a greater frequency of hematopoietic colonies than multiple clones of K-iPSCs, and more colonies than iPSCs isolated from adult CD34 + blood and keratinocytes ( Supplementary Fig. 2a-c) . However, neither CB-iPSCs nor K-iPSCs showed a difference in tissue differentiation potential into definitive endoderm (Supplementary Fig. 2d ).
To analyze genome-wide DNA methylation patterns, we compared multiple CB-iPSC and K-iPSC lines and their parental somatic cells to human ESCs using comprehensive, high-throughput, arraybased, relative methylation (CHARM) analysis, which interrogates 5.2 million CpG sites, including virtually all CpG islands and shores 4 . We determined the number of differentially methylated regions (DMRs) in pair-wise comparisons, using a threshold area cutoff of 2, corresponding to an approximate 5% false discovery rate (FDR) 5 ( Fig. 2a and Supplementary Table 1) . We confirmed the results of CHARM analysis by bisulfite pyrosequencing of multiple loci ( Supplementary Fig. 3 ).
Unsupervised hierarchical clustering using the 1,000 most variable probes across samples revealed that CB-iPSCs are easily distinguished from K-iPSCs (Fig. 2b) . ESCs cluster with both CB-iPSCs and K-iPSCs, suggesting that the separation between CB-iPSCs and K-iPSCs is not due to different levels of pluripotency, as confirmed by gene expression profiling and analysis of binding of the pluripotency core transcription factor to the DMRs that distinguish CB-iPSCs and K-iPSCs Fig. 4) . We found that 581 of the 1,519 differentially expressed genes are located in or near DMRs that distinguish cord blood cells from keratinocytes (1.73-fold more than expected by chance; P < 10 −5 ). We also found that 27 of these 581 genes are in or near DMRs that distinguish CB-iPSCs and K-iPSCs (Supplementary Table 2 ), a 2.55-fold enrichment over that predicted by chance (P < 10 −4 , Fig. 2c ). This enrichment persists even when pluripotency-related genes defined by compiled microarray data 6 are removed from the gene set (Supplementary Fig. 5a ). Further, 17 of the 581 genes overlap DMRs that distinguish CB-iPSCs from ESCs, a fourfold enrichment over that predicted by chance (Supplementary Fig. 5b ).
Several lines of evidence support a direct mechanistic link between differential methylation and biased lineage differentiation of iPSC lines. First, a literature survey of the genes associated with the top ten DMRs that distinguish CB-iPSCs from K-iPSCs indicates that five are associated with hematopoiesis, and four with epithelial cell phenotypes (Supplementary Table 3 ). Second, K-iPSCs maintained gene-body methylation, a phenomenon generally correlated with gene expression 7 , for numerous keratinocyte-associated genes. Of 185 gene bodies hypermethylated in K-iPSCs compared to CB-iPSCs, 14 correspond to tissue DMR-associated genes that are expressed in keratinocytes, a threefold enrichment over that predicted by chance (Fig. 2d) . Conversely, of 19 gene bodies hypomethylated in CB-iPSCs compared to ESCs, four correspond to DMR-associated genes highly expressed in keratinocytes (P = 0.021), including the keratinocytespecific transcription factor RIPK4. Taken together, our analysis supports the notion that the reprogramming process can leave residual methylation marks associated with both expression and repression of tissue-specific genes.
To determine whether the 370 DMRs that distinguish CB-iPSCs and K-iPSCs (Supplementary Table 1) represented residual methylation left over from the tissue of origin or were instead de novo and potentially aberrant methylation signatures generated during reprogramming, we compared the state of these regions in cord blood cells, keratinocytes and ESCs. Seventy-five residual DMRs were found in cord blood cells and keratinocytes, 28 DMRs were specific for ESCs and 267 DMRs were newly generated during reprogramming, reminiscent of our prior observation of frequent de novo DMRs in mouse iPSCs of fibroblast cell origin from aged donors 1 . 3,500 
Using ESCs as a reference, both CB-iPSC and K-iPSC DMRs were highly enriched for tissue-of-origin DMRs (P < 0.0001).
In studies of murine induced pluripotent stem cell lines, epigenetic memory can be erased over time by extended culture 2 or ectopic gene expression 1 . During extended culture of K-iPSC clones N9 and G6 and CB-iPSC clone 6, the K-iPSC N9 clone showed a gradual increase in blood-forming potential (Supplementary Fig. 6a ), but erasure of epigenetic memory by passaging did not occur in all clones. HOXD8 was one of 27 DMR-associated genes in the somatic cell types that was more highly methylated in keratinocytes and K-iPSCs relative to cord blood cells and CB-iPSCs, respectively (Supplementary Fig. 3a) . Notably, at the higher passages of a K-iPSC clone (N9), the restored blood-forming potential coincided with a reduction of HOXD8 expression and methylation ( Supplementary  Fig. 6b,c) . The HOXD8 DMR overlaps with a CTCF binding site, which may control HOXD8 expression 8 (Supplementary Fig. 6d ). Because HOX genes exert major effects on blood cell differentiation, we hypothesized that expression of HOXD8 might be playing a role in inhibiting blood-forming potential in early passage K-iPSCs in the clone N9. Consistent with a negative effect of HOXD8 expression on blood development, we observed that ectopic expression of HOXD8 in CB-iPSCs reduced blood-forming potential (Supplementary Fig. 6e ), as did restoring high levels of HOXD8 in later passages of K-iPSC clone N9 (Supplementary Fig. 6f ). In contrast, short hairpin RNAmediated HOXD8 knockdown in the K-iPSC clone G6 substantially improved its hematopoietic capacity (Supplementary Fig. 6g ). These data correlate differential methylation and expression of the HOXD8 locus with blood-forming potential in iPSC lines. However, further CHARM analysis of early and late passages of the clone N9 indicates that extended tissue culture did not make the cells epigenetically closer to ESCs ( Supplementary Fig. 6h) ; rather, extended passage may have had locus-specific effects that influence the differential potential of iPSCs.
Prior studies comparing human iPSCs to ESCs have found that iPSCs are differentially methylated 5, 7, 9 and exhibit significant reprogramming variability [10] [11] [12] , and recently a transcriptional memory of somatic cells in human iPSCs has been reported 13 . However, a link has not yet been identified between disparate methylation signatures at multiple loci and altered differentiation potential. Here we find that methylation at loci important to tissue fate persists as a form of epigenetic memory even in human iPSCs that pass stringent criteria for pluripotency typically applied to human cells. CB-iPSCs and K-iPSCs retain residual epigenetic marks on a small number of genes, which nonetheless appear sufficient to skew differentiation potential toward the tissue of origin. Similarly, even in murine iPSCs characterized by the more stringent assays of pluripotency available in mice (e.g., blastocyst chimerism and germline transmissibility), we detected methylation signatures diagnostic of the tissue of origin and documented a preference to differentiate along the lineage of the donor cell 1 . The epigenetic signatures of the tissue of origin that are retained in iPSCs reflect the technical limitations of reprogramming.
Although most differences among iPSCs, or between iPSCs and ESCs, represent random or stochastic differences, we observed in our experiments that residual epigenetic marks reflecting the tissue of origin can skew differentiation potential. Ultimately, refined methods of reprogramming may generate iPSCs that more closely approximate the epigenome of embryo-derived stem cells. Alternatively, more permissive differentiation conditions, either in vitro or in vivo, may overcome residual epigenetic barriers. Regardless, before clinical applications, the in vivo behavior of in vitro-differentiated cells derived from iPSCs of a wider range of donor tissues by various differentiation protocols and culture conditions will require substantial evaluation. A differentiation bias of existing iPSCs may be advantageous in certain research and therapeutic applications, especially as directed differentiation of pluripotent cells to tissues of interest remains a challenge for the field.
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